Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1844537rdf:typepubmed:Citationlld:pubmed
pubmed-article:1844537lifeskim:mentionsumls-concept:C0021311lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C2754943lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C0040557lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C1510996lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C2745888lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:1844537lifeskim:mentionsumls-concept:C0332185lld:lifeskim
pubmed-article:1844537pubmed:issue3lld:pubmed
pubmed-article:1844537pubmed:dateCreated1993-5-10lld:pubmed
pubmed-article:1844537pubmed:abstractTextFor serologically characterizing a recent primary toxoplasma infection, the low avidity of IgG specific antibodies was studied. Avidity was evaluated as the decrease of IgG antibody titers in ELISA after treating plates with 6 M urea, as a dissociating solution of low avidity antigen-antibody complexes. Sixty nine serum samples were studied, presenting characteristic patterns of recent, transitional or chronic toxoplasmosis. Serological patterns were determined according to results of IgG and IgM immunofluorescence, IgM-capture, and hemagglutination tests. Twenty three serum samples from each of the referred patterns I, II and III were titrated. For chronic toxoplasmosis infections, which presented a serological pattern III, observed decrease of titers was 3% +/- 3%. For pattern I recent toxoplasmosis sera it was 34% +/- 12%, and for transition pattern II, 12% +/- 9%. Thus, a low avidity of IgG specific antibodies can be applicable for the diagnosis of a recent toxoplasmosis infection.lld:pubmed
pubmed-article:1844537pubmed:languageporlld:pubmed
pubmed-article:1844537pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1844537pubmed:citationSubsetIMlld:pubmed
pubmed-article:1844537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1844537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1844537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1844537pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1844537pubmed:statusMEDLINElld:pubmed
pubmed-article:1844537pubmed:issn0036-4665lld:pubmed
pubmed-article:1844537pubmed:authorpubmed-author:CamargoM EMElld:pubmed
pubmed-article:1844537pubmed:authorpubmed-author:LeserP GPGlld:pubmed
pubmed-article:1844537pubmed:authorpubmed-author:da SilvaS MSMlld:pubmed
pubmed-article:1844537pubmed:authorpubmed-author:GranatoC HCHlld:pubmed
pubmed-article:1844537pubmed:issnTypePrintlld:pubmed
pubmed-article:1844537pubmed:volume33lld:pubmed
pubmed-article:1844537pubmed:ownerNLMlld:pubmed
pubmed-article:1844537pubmed:authorsCompleteYlld:pubmed
pubmed-article:1844537pubmed:pagination213-8lld:pubmed
pubmed-article:1844537pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:meshHeadingpubmed-meshheading:1844537-...lld:pubmed
pubmed-article:1844537pubmed:articleTitle[Avidity of specific IgG antibodies as markers of recent primary infection caused by Toxoplasma gondii].lld:pubmed
pubmed-article:1844537pubmed:affiliationLaboratório Fleury de Análises Clínicas, São Paulo, Brasil.lld:pubmed
pubmed-article:1844537pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1844537pubmed:publicationTypeEnglish Abstractlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1844537lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1844537lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1844537lld:pubmed